Physician profile
John C Ervin
NPI 1730153099
$3,546.07
in general payments reported to CMS, 2019-2025
23 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $305 · 2021: $293 · 2022: $360 · 2023: $290 · 2024: $459 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,010.34 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Allergan, INC. | $462.76 | 2019-2022 | |
| Abbvie INC. | $394.76 | 2022-2025 | |
| Dompe US, INC. | $289.31 | 2021-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $209.95 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $166.64 | 2023-2025 | Miebo, Xiidra |
| Carl Zeiss Meditec USA, INC. | $127.98 | 2022 | |
| Astellas Pharma US INC | $124.66 | 2024 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $116.46 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $115.23 | 2019 | |
| Aerie Pharmaceuticals, INC. | $106.30 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $77.02 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $67.18 | 2022-2025 | Tecnis Iol, Catalys System, Veritas Vision System |
| Glaukos Corporation | $57.33 | 2023-2025 | Idosetr, Kxl System (Not Refurbished) |
| Apellis Pharmaceuticals, INC. | $48.07 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $35.94 | 2025 | Omidria |
| Oyster Point Pharma, INC. | $32.14 | 2022-2024 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $26.71 | 2020-2021 | |
| Horizon Therapeutics Plc | $24.26 | 2022 | |
| Thea Pharma INC. | $20.78 | 2023 | Iyuzeh |
| Rxsight INC | $17.94 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Shire North American Group INC | $14.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ervin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.